Melanoma laboratory tests: Difference between revisions
Jump to navigation
Jump to search
YazanDaaboul (talk | contribs) |
YazanDaaboul (talk | contribs) |
||
| Line 7: | Line 7: | ||
==Laboratory Findings== | ==Laboratory Findings== | ||
*There are no laboratory findings associated with the diagnosis of melanoma. Measurement of serum LDH may be considered for follow-up among patients who have been diagnosed with stage IB-IV melanoma | *There are no laboratory findings associated with the diagnosis of melanoma. Measurement of serum LDH may be considered for follow-up among patients who have been diagnosed with stage IB-IV melanoma.<ref name="pmid23584343">{{cite journal| author=Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A et al.| title=Melanoma, version 2.2013: featured updates to the NCCN guidelines. | journal=J Natl Compr Canc Netw | year= 2013 | volume= 11 | issue= 4 | pages= 395-407 | pmid=23584343 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23584343 }} </ref> | ||
===LDH=== | ===LDH=== | ||
*Once metastatic melanoma is diagnosed, serum [[lactate dehydrogenase]] (LDH) may be helpful for follow-up. | *Once metastatic melanoma is diagnosed, serum [[lactate dehydrogenase]] (LDH) may be helpful for follow-up.<ref name="pmid23584343">{{cite journal| author=Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A et al.| title=Melanoma, version 2.2013: featured updates to the NCCN guidelines. | journal=J Natl Compr Canc Netw | year= 2013 | volume= 11 | issue= 4 | pages= 395-407 | pmid=23584343 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23584343 }} </ref> | ||
*For patients with stage IB-IV melanoma, measurement of serum LDH may be considered every 6-12 months. | *For patients with stage IB-IV melanoma, measurement of serum LDH may be considered every 6-12 months.<ref name="pmid23584343">{{cite journal| author=Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A et al.| title=Melanoma, version 2.2013: featured updates to the NCCN guidelines. | journal=J Natl Compr Canc Netw | year= 2013 | volume= 11 | issue= 4 | pages= 395-407 | pmid=23584343 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23584343 }} </ref> | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 03:25, 22 August 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Yazan Daaboul, M.D.; Serge Korjian M.D.
|
Melanoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Melanoma laboratory tests On the Web |
|
American Roentgen Ray Society Images of Melanoma laboratory tests |
|
Risk calculators and risk factors for Melanoma laboratory tests |
Overview
There are no laboratory findings associated with the diagnosis of melanoma. Serum lactate dehydrogenase (LDH) may be elevated among patients with metastasis.
Laboratory Findings
- There are no laboratory findings associated with the diagnosis of melanoma. Measurement of serum LDH may be considered for follow-up among patients who have been diagnosed with stage IB-IV melanoma.[1]
LDH
- Once metastatic melanoma is diagnosed, serum lactate dehydrogenase (LDH) may be helpful for follow-up.[1]
- For patients with stage IB-IV melanoma, measurement of serum LDH may be considered every 6-12 months.[1]